B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
News / Health Access / Regulatory Affairs / Small Business
Emanate Receives FDA 510(k) Clearance for Perio PODS™, the First FDA-Cleared At-Home Periodontal Wound Dressing Indicated Following Non-Surgical Periodontal Procedures
September 18, 2026
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Emanate Biomedical, Inc., a medical technology company creating a new category of clinician-directed at-home oral care, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for Perio PODS™, a periodontal wound dressing consisting of single-use, patient-matched dental trays preloaded with engineered hydrogel.
Event / Digital Health / Regulatory Affairs
Shifting Customer Engagement Models in Diagnostics: Winning in a Rapidly Evolving Market
September 29, 2026
2:00 PM – 3:00 PM
Join Deloitte in this discussion examining how rising consumer expectations, new technology entrants, and evolving provider roles are reshaping how diagnostics manufacturers engage their customers.
Event / Digital Health / Regulatory Affairs
Reimagining the Cost of Quality: The Agentic AI Opportunity for MedTech
September 30, 2026 10:00AM – 11:00AM ET
Join HCLTech in this discussion about practical use cases and strategies to scale AI-driven quality operations while maintaining compliance and enabling greater innovation.
News / Coverage & Payment / Health Access / Regulatory Affairs
AdvaMed Welcomes Expiration of Moratorium on New Medicare Durable Medical Equipment Suppliers
August 27, 2026
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the medtech association, today welcomed the expiration of the moratorium on Medicare acceptance of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) suppliers. He made the following comment on the expiration.
Global & Trade
AdvaMed® Resources for Colombia Earthquake Response
Learn how AdvaMed® member companies can support earthquake relief efforts in Columbia through medical supply donations, logistics assistance, financial contributions, and other humanitarian response initiatives.
News / Diagnostics / Medical Imaging / Regulatory Affairs
Cubresa Announces FDA 510(k) Clearance for the Cubresa BrainPET™ Scanner, Opening New Frontier in Clinical Brain Imaging
August 20, 2026
WINNIPEG, MANITOBA, CANADA, August 20, 2026 /EINPresswire.com/ — Cubresa Inc., a global leader in clinical and preclinical molecular imaging technologies, today announced that it has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its groundbreaking Cubresa BrainPET™ scanner.
News / Diagnostics / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Statement on the Nomination of Dr. Heidi Overton as FDA Commissioner
August 19, 2026
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on President Trump’s nomination of Dr. Heidi Overton to serve as FDA commissioner.
Event / Digital Health / Regulatory Affairs
Software as a Medical Device: From Regulatory Strategy to Market Readiness
September 16, 2026
12:00 PM – 1:00 PM
Join MIDI as they provide a practical framework for developing SaMD products with regulatory requirements built into the development process.